| Cash and cash equivalents | 101.63M |
| Accounts receivable | 18.3M |
| Prepaid expenses and other current assets | 4.77M |
| Total current assets | 134.87M |
| Land, property and equipment, net | 64.98M |
| Acquired technology and other intangibles, net | |
| Other non-current assets | 2.88M |
| Total assets | 210.25M |
| Liabilities and Stockholders' Equity | |
| Accounts payable and other accrued liabilities | |
| Accrued compensation | |
| Accrued clinical and preclinical study fees | 6.53M |
| Accrued restructuring | |
| Current portion of deferred revenues | 22.52M |
| Current portion of derivative liabilities | |
| Current portion of lease financing obligations | |
| Total current liabilities | 60.51M |
| Deferred rent | |
| Deferred revenues, less current portion | 82.13M |
| Derivative liabilities, less current portion | |
| Lease financing obligations, less current portion | |
| Commitments and contingencies and subsequent events | 0 |
| Common stock | 24K |
| Additional paid-in capital | 1.44B |
| Treasury stock, at cost | |
| Accumulated other comprehensive income | 867K |
| Accumulated deficit | -1.44B |
| Total stockholders' equity | 3.33M |
| Total liabilities and stockholders' equity | 210.25M |
| Liabilities and Stockholders' Equity | |
| Current portion of note payable | |
| Note payable | |
| Liabilities and Stockholders' Equity | |
| Current portion of note payable | |
| Note payable | |